Novartis AG Falls Tuesday
This article was automatically generated using Dow Jones technology. Shares of Novartis AG slipped 0.2% to CHF98.90 Tuesday on what proved to be an overall poor trading session for the stock market,
Here's Why Aristotle Capital's International Equity Composite Sold Novartis AG (NVS)
Here's Why Novartis (NVS) Is a Strong Value Stock
MorphoSys Declares Voluntary Delisting From Nasdaq
Express News | Novartis AG : Morgan Stanley Raises Target Price to $114 From $110
Top Gap Ups and Downs on Thursday: IBKR, DAL, VOD and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Novartis On Pace for Record High Close -- Data Talk
Novartis AG Sponsored ADR (NVS) is currently at $108.97, up $0.74 or 0.68% --Would be new all-time high (Based on available data back to Dec. 24, 1996) --Would be the first record close since Jan. 22,
Top Gap Ups and Downs on Tuesday: BABA, TTE, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Citi Research's AI Hedge Stocks - Part II
Novartis on Track for Record High Close -- Data Talk
Novartis AG Sponsored ADR (NVS) is currently at $108.68, up $0.55 or 0.51% --Would be new all-time high (Based on available data back to Dec. 24, 1996) --Would be the first record close since Jan. 22,
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief
Lexicon Pharmaceuticals (LXRX) said Monday it has named Mike Exton as chief executive and Jeff Wade as chief operating officer.The company said Exton succeeds Lonnel Coats, who has retired.Exton most
UBS Sticks to Their Buy Rating for Novartis AG (NOVN)
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees an
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches
The Association of the British Pharmaceutical Industry's Prescription Medicines Code of Practice Authority flagged four major pharmaceutical companies for breaching its regulations. The British trade
Novartis AG (NOVN) Gets a Hold From Citi
Citi analyst Peter Verdult maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF97.00.
Top Gap Ups and Downs on Tuesday: TSLA, MUFG, SMFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinica
Novartis Is Maintained at Buy by Jefferies
Novartis Is Maintained at Buy by Jefferies
Express News | Jefferies Maintains Buy on Novartis, Raises Price Target to $122.5
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 15.08% Jefferies $121 → $122.5 Maintains Buy 04/24/2024 8.97% BMO Capital $114 → $116 Maintains